« Back to news

Two New Stakeholder Directors join Stevenage Bioscience Catalyst Board - Continued support from GSK and Wellcome as campus evolves

Two New Stakeholder Directors join Stevenage Bioscience Catalyst Board - Continued support from GSK and Wellcome as campus evolves

 

Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is pleased to announce that Dave Allen of GSK and Daniel Nelki of Wellcome have joined its Board. As representatives of major stakeholders and experts in innovation, they will help drive the evolution of the campus into its next phase of development. They replace Ian Tomlinson, now independent Chairman of the SBC Board, and John Cooper, who retired recently, respectively.

Dave Allen is the head of the Respiratory Therapy Area at GSK, responsible for the identification of novel medicines and their progression to global registration.  He leads a group of over 200 scientists and clinicians addressing major unmet needs in this therapeutic area and is GSK’s Chief Chemist.  Dave joined the company as are search chemist after completing his studies, and has also worked on antibiotics and cardiovascular medicines. 

Daniel Nelki is the Science to Health lead and part of the Management Team of the Innovations Division at Wellcome, supporting its translational activities. Prior to joining the charity, he was a post-doctoral researcher in the area of mouse molecular genetics and then qualified as a solicitor specialising in intellectual property and commercial law.

Ian Tomlinson, Chairman of the SBC Board, said, 'As representatives of two of our stakeholders and experts in healthcare innovation, we are delighted to welcome Dave and Daniel to the SBC Board. With the Accelerator now occupied by MRC Technology and Tusk Therapeutics, and the Cell and Gene Therapy Catapult's manufacturing centre opening in 2017, these are exciting times at SBC. The insight of our new Stakeholder Directors will be invaluable as we grow further.'

Share this: